期刊文献+

白细胞介素-11合维血宁治疗白血病化疗后血小板减少 被引量:2

Clinical Observation of RhIL-11 Integrated with Weixuening Granule in Treating the Decrease of Blood Platelet of Leucocythemia after Chemical Therapy
下载PDF
导出
摘要 目的:观察重组白细胞介素-11(rhIL-11)、维血宁干扰预防白血病化疗后血小板下降的临床疗效。方法:急性白血病患者共27例,观察组15例,化疗后应用巨和粒、维血宁治疗;对照组12例单纯化疗,观察两组对血小板下降的影响。结果:观察组血小板最低值明显高于对照组,血小板恢复亦明显快于对照组,骨髓巨细胞数明显高于对照组(P<0.05)。结论:rhIL-11结合维血宁在预防白血病化疗后血小板下降有明显的提升作用,能减少血小板输注的次数。 Objective:To observe the clinical effect of rhil-ll integrated with weixuening granule in treating the decrease of blood platelet of leuoocythemia after chemical therapy. Methods:IS cases with acute leucocythemia after chemical therapy were treated by rhil-ll and weixuening granule. The improving effects on the decrease of blood platelet were observed. Results: The lowest value of blood platelet in the treatment group was obviously higher than that in the contrast group. The recoverable time of blood platelet in the treatment group was also obviously shortened than that in the contrast group. The numbers of myelogenous huge cells were significantly more than that in the contrast group (P〈0.05 ). Conclusion: Rhil-11 integrated with weixuening granule has a good effect in preventing the decrease of blood platelet of leucocythemia after chemical therapy and then can reduce the injection time of blood platelet.
作者 陈育生
出处 《浙江中西医结合杂志》 2006年第9期541-542,共2页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
关键词 白血病 化疗 血小板减少 白介素-11 维血宁颗粒 leucocythemia, blood platelet, rhil-ll, weixuening granule
  • 相关文献

参考文献2

二级参考文献13

  • 1Kaushansky K. Use of thrombopoietic growth factors in acute leukemia [J]. Leukemia, 2000,14(3) :505-508.
  • 2Saitoh M, Taguchi K, Momose K, et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells[J]. Cancer Chemother Pharmacol, 2002, 49(2): 161-166.
  • 3Opal SM, Jhung JW, Keith JC Jr. et al. Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis[J]. Blood, 1999,93 (10): 3467-3472.
  • 4Weich NS, Fitzgerald M, Wang A. et al. Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro[J]. Blood, 2000, Jan1S;95(2):503-509.
  • 5Ellis M, Zwaan F, Hedstrom U, et al. Recombinant human interleukin 11 and bacterial infection in patients with [correction of]haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial [J]. Lancet, 2003,361(9354): 275-280.
  • 6Saitoh M, Taguchi K, Momose K. et al. Recombinant human interleukin-11 improved earboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. [J ]Cancer Chemother Pharmacol, 2002,49(2): 161-166.
  • 7Reynolds CH. Clinieal effieacy of rhIL-11[J].Oncology(Huntingt),2000,14(9 Suppl 8) :32-40.
  • 8Ghalib R,Levine C,Hassan M, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis[J]. Hepatology, 2003,37(5): 1165-1171.
  • 9BusselJB,MukherjeeR, StoneAJ. A pilot study of rhuIL-11 treatment of refractory ITP[J].Am J Hematol, 2001,66(3): 172-177.
  • 10Soda H, Raymond E, Sharma S, et al. Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors[J]. Anticancer Drugs, 1999,10(1): 97-101.

共引文献35

同被引文献4

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部